drugset / Trial / NCT00992381

Comparison Study of a New Combination of 2 Marketed Medications (Esomeprazole and Naprosyn) Versus Naprosyn Alone

NCT00992381

Phase 1 Completed 24 enrolled AstraZeneca POZEN · collab
RandomizedCrossoverSingle-blindBasic science

Summary

The purpose of this study is to determine whether the absorption of naproxen from the PN 400 combination (Naprosyn and Esomeprazole) tablets is similar to that from the naproxen tablets (Naprosyn®), which are currently sold in Australia.

Timeline

Start
2009-09
Primary completion
Completion
2009-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Esomeprazole Small molecule 20 mg
Subject Naproxen Small molecule 500 mg

Indications

No indication recorded.